Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
The Dangers of PRES
Neurol 92:e282-e285, Chaterine, C.,et al, 2019
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
Progressive Visuospatial Problems in a 71-Year-Old Man
Neurol 83:e6-e10, Symmonds, M.,et al, 2014
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab
NEJM 354:980-982, Ozcan,C.,et al, 2006
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005
Central Nervous System Lymphoma Associated with Mycophenolate Mofetil in Lupus Nephritis
Lupus 14:910-913, Dasgupta,N.,et al, 2005
Treatment-Induced Leukoencephalopathy in Primary CNS Lymphoma,A Clinical and Autopsy Study
Neurol 62:451-456, Lai,R.,et al, 2004
Cerebral Toxoplasmosis Following Etanercept Treatment for Idiophatic Pneumonia Syndrome after Autologous Peripheral Blood Progenitor Cell Transplantation (PBPCT)
Ann Hematol 82:649-653, Gonzalez-Vicent, M.,et al, 2003
Reversible Tacrolimus-Induced Neurotoxicity Isolated to the Brain Stem
AJNR 21:1251-1254, Oliverio,P.J. et al, 2000
Cerebral Vasculitis During FK 506 Treatment in a Liver Transplant Patient
Neurol 50:1154-1157, Pizzolato,G.P.,et al, 1998
Neuroimaging Findings in Patients on Immunosuppressive Therapy:Experience with Tacrolimus Toxicity
AJR 166:683-688, Appignani,B.A.,et al, 1996
Multiple Cerebral Lesions Complicating Therapy with Interleukin-2
Neurol 47:417-424, Karp,B.I.,et al, 1996
Linomide Reduces the Rate of Active Lesions in Relapsing-Remitting Multiple Sclerosis
Neurol 47:895-900, Anderson,O.,et al, 1996
Immunosuppression-Induced Leukoencephalopathy from Tacrolimus (FK506)
Ann Neurol 40:575-580, Small,S.L.,et al, 1996
MR Imaging of Reversible Cyclosporin A-Induced Neurotoxicity
AJR 157:851-859, Truwit,C.L.,et al, 1991
Cyclosporine-Related Central Nervous System Toxicity in Cardiac Transplantation
NEJM 323:420-421, Hughes,R.L., 1990
Clinical Presentation, Investigation Findings, and Outcomes of IgG4-Related Pachymeningitis,A Systematic Review
JAMA Neurol 82:193-199, Terrim,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Immunosuppressive Therapy Reversing Obstructive Hydrocephalus in CLIPPERS
Neurol 102:e209396, Yang,Y.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Clinicopathologic Conference, Cerebral Amyloid Angiopatny-Related Inflammation
NEJM 385:358-368, Case 22-2021, 2021
A 47-Year-Old With Headache, Vertigo, and Double Vision
Neurol 97:e535-e539, Frey, J.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
A Woman in her 40s with Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss
JAMA Neurol 76:504-505, Roshal, D.A.,et al, 2019
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation
JAMA Neurol 73:197-202, Auriel, E.,et al, 2016
Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
A Case of Subacute Cognitive Decline in a 76-year-old Man
Neurol 87:e124-e128, MacLellan, A.,et al, 2016
Inflammatory Muscle Diseases
NEJM 372:1734-1747, Dalakas, M.C., 2015
Reactivation of Herpesvirus under Fingolimod: A Case of Severe Herpes Simplex Encephalitis
Neurol 84:2377-2378, Pfender, N.,et al, 2015
Very Late-Onset Neuromyelitis Optica Spectrum Disorder Beyond the Age of 75
J Neurol 262:1379-1384, Krumbholz, M.,et al, 2015
Nocardiosis of the Central Nervous System
Medicine 93:19-32, Anagnostou, T.,et al, 2014